Randomized Controlled Phase 2 Study to Evaluate Iptacopan in Participants with Active ANCA-Associated Vasculitis (AAV): Interim Renal-Focused Results (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-OR077; Pres time: Oct 24, 2026; 05:18 PM - 05:30 PM; Location: Four Seasons Ballroom 2, Convention Center; P2 | "Methods The study comprises a 24-week (W) double-blind induction period (iptacopan 200mg twice daily vs PBO), each in combination with rituximab [RTX] and protocol-defined glucocorticoid (GC) taper, followed by a 24W open-label maintenance period. Target engagement was demonstrated by a robust reduction in complement biomarkers. Iptacopan in combination with RTX and GC taper was generally well tolerated, with a safety profile in line with other iptacopan studies."
Clinical • Late-breaking abstract • P2 data • ANCA Vasculitis • Infectious Disease • Vasculitis
|
|
Grégory Pugnet; Benjamin Terrier; Christian Löffler; Zhanzheng Zhao; Sebastian Juan Magri; Jorge Alejandro Brigante; Fatma Alibaz-Oner; Rachel B. Jones; Min Chen; Rodolfo Nicolas Alvarado; Adrian Schreiber; Anna Bazsó; Albrecht Betrains; Shilpa Muthusamy; Malika Hanser; Julia Wagner; Swati Ghanshani; Prasanna Kumar Nidamarthy; Imelda Schuhmann; Guido Junge
|